Abstract

Colorectal cancer is a major public health problem worldwide, and a major cause of mortality and morbidity. Correct pretherapeutic staging has the role of guiding the management of colon cancer patients. The diagnosis is guided by the clinical symptoms. Chemotherapy is an important part of colon cancer treatment. Chemotherapy regimens are adapted to tumor stage and patient status and have various side effects and variable survival outcomes. International guidelines recommend different treatments depending on the presence or absence of metastases. The primary goal of treatment in nonmetastatic colon cancer is surgical removal of the tumor which could be the first step of the complex therapy or preceded by neoadjuvant therapy, depending on pretherapeutic staging. In resectable nonmetastatic tumors the preferred surgical procedure is colectomy with en bloc removal of regional lymph nodes. The extent of colectomy should be based on tumor location. The management of metastatic colon cancer also targets the therapeutic approach of the metastatic disease. Therapy is standardized and applied according to tumor stage. Surveillance has a major role in therapeutic success, reason why a time schedule and a protocol adapted to the primary lesion are essential. The goal of implementing the recommendations of international guidelines for the treatment of colon cancer is to provide a uniform treatment for this disease in view of improving overall survival of patients.

Highlights

  • According to the World Health Organization in 2010 cancer overtook ischemic heart disease as a leading cause of death [1]

  • The benefits of doublet scheme with oxaliplatin and 5-flurouracil/ Leucoverin (5-FU/LV) (FOLFOX scheme) have been demonstrated by a number of clinical trials that showed a significant increase in disease-free interval after 3 years, and a 23% reduction in relapse rate compared to patients receiving only 5FU/LV [8]

  • Colon cancer is a major public health problem. The treatment of this cancer is standardized, and the recommendations from international guidelines are specific to tumor stage

Read more

Summary

Introduction

According to the World Health Organization in 2010 cancer overtook ischemic heart disease as a leading cause of death [1]. Surveillance includes history and physical examination every 3-6 months for 2 years, every 6 months for 5 years; carcinoembryonic antigen every 3-6 months in the first 2 years, every 6 months for 3-5 years; chest-abdominal-pelvic CT every 3-6 months in the first 2 years, every 6-12 months for 5 years; colonoscopy in 1 year, if no preoperative colonoscopy due to obstructive lesion, and in case of preoperative colonoscopy in 3-6 months, repeated at 1 year if advanced adenoma or at 3 years and every 5 years if not advanced adenoma [9]; Unresectable synchronous liver and/or lung metastases: 1) FOLFIRI or FOLFOX or CapeOx ± bevacizumab. If a tumor recurrence is found administer the treatment recommended for metastatic disease [9]

Conclusions
Conflict of interest
Findings
National Comprehensive Cancer Network
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call